[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies


Description

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Trial Eligibility

Key Inclusion Criteria: 1. Age ≥ 18 and ≤ 65 years at the time of enrollment 2. Diagnosed acute myeloid, lymphoid or mixed phenotype leukemia, or high or very high risk myelodysplasic syndrome (MDS), myelofibrosis, or chronic myeloid leukemia 3. Planned to undergo myeloablative allogeneic hematopoietic stem cell transplant (HCT) 4. Matched to a 8/8 or 7/8 related or unrelated donor, or to a related haploidentical donor 5. Estimated glomerular filtration rate (eGFR) \> 50 mL/minute 6. Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA) 7. Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50% 8. Total bilirubin \< 1.5 times upper limit of normal (ULN) (\< 3 times if attributed to Gilbert's syndrome) and ALT/AST \< 3 times ULN Key Exclusion Criteria: 1. Prior allogeneic HCT 2. Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed. 3. Planned donor lymphocyte infusion (DLI) 4. Positive anti-donor HLA antibodies against a mismatched allele in the selected donor 5. Karnofsky performance score \< 70% (Appendix 12.7) 6. Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) \> 4 (Appendix 12.8) 7. Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment 8. Seropositive for HIV-1 or -2, HTLV-1 or -2 9. Any uncontrolled autoimmune disease requiring active immunosuppressive treatment 10. Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected 11. History of idiopathic or secondary myelofibrosis 12. Women who are pregnant or breastfeeding

Study Info

Organization

Orca Biosystems, Inc.


Primary Outcome

Number of Dose Limiting Toxicities


Outcome Timeframe 28 Days after administration of Orca-Q/OrcaGraft

NCTID NCT03802695

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2019-04-08

Completion Date 2026-04

Enrollment Target 186

Interventions

BIOLOGICAL OrcaGraft (Orca-Q)

Locations Recruiting

City of Hope

United States, California, Duarte


UC Davis

United States, California, Sacramento


Stanford Health Care

United States, California, Stanford


Emory University

United States, Georgia, Atlanta


The University of Kansas Hospital

United States, Kansas, Kansas City


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Lymphoblastic Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.